Navigation Links
Multigene Test Predicts Who Could Avoid Chemotherapy Despite Positive Lymph Nodes in Early Breast Cancer
Date:12/13/2007

SAN ANTONIO, Texas, Dec. 13 /PRNewswire/ -- Kathy S. Albain, MD, of Loyola University Chicago, presented new data showing for the first time the predictive value of the 21-gene Recurrence Score (RS) assay in patients with node-positive breast cancer. The Breast Cancer Intergroup of North America trial conducted by the Southwest Oncology Group (SWOG 8814) originally showed that patients treated with 6 cycles of chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil followed by 5 years of tamoxifen (CAF-T) had superior disease-free survival (DFS) and overall survival (OS) compared with patients treated with tamoxifen alone. This RS assay was performed on the breast cancer tumor specimens collected on this trial, and measured the same groups of genes already in use to predict outcomes and chemotherapy benefit in lymph node-negative disease. Up until this study, standard practice was to give chemotherapy to women with positive nodes. This study sought to determine if the RS assay would be useful to predict who might avoid chemotherapy.

Dr Albain's group first showed that the RS is prognostic for 10-year DFS and OS in patients treated with tamoxifen alone. They then compared DFS in patients treated with tamoxifen versus patients treated with CAF-T across RSs. They found that there was a large and significant benefit in DFS over 10 years from adding CAF in patients with a high RS. In contrast, there was no benefit in patients with a low RS. Interaction between CAF benefit and the linear RS was significant overall and in the first 5 years. There was a strong carryover benefit of CAF in high RSs out to 10 years, but no effect whatsoever in low RSs long term. This interaction of RS with treatment effect was true in greater than or equal to 4 positive nodes and 1 to 3 positive nodes.

In summary, this work demonstrates that: (1) a very strong benefit from chemotherapy with CAF is predicted when the RS is high, and that (2) a low RS may define a group of women with positive nodes who do not appear to benefit from anthracycline-based chemotherapy.

Dr Albain concluded, "These data collectively challenge chemotherapy mandates for patients with node-positive, ER-positive disease: not all benefit from chemotherapy, whereas others derive greater benefit than previously predicted. SWOG 8814 joins a suite of studies that provide a consistent message regarding the value of the RS for individualized adjuvant therapy, and for the first time shows its value in a population of women with node-positive breast cancer who were treated with a tamoxifen-alone control. These findings should be discussed with women diagnosed with early breast cancer who fit the criteria for this study."


'/>"/>
SOURCE San Antonio Breast Cancer Symposium
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. The next generation: nanomagnets could replace semiconductors
2. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
3. Nanotech could make solar energy as easy and cheap as growing grass
4. Bone-growing nanomaterial could improve orthopaedic implants
5. Stem Cell Breakthrough Could End Human Embryonic Experimentation
6. FED-TVs with carbon nanotube technology could supersede plasma and LCD flat screens
7. Blue dye could hold the key to super processing power
8. ORNL super water repellent could cause big wave in market
9. Tethered to chip, energy supply that drives sperm could power nanobot
10. DelSite Nasal Powder Technology Could Reduce Recently Reported Waste in Federal Vaccine Program
11. First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... DrugDev believes ... standardization and a beautiful technology experience. All three tenets were on display at the ... trial leaders from over 40 sponsor, CRO and site organizations to discuss innovation and ...
(Date:12/2/2016)... The immunohistochemistry (IHC) market is projected to reach ... during the forecast period of 2016 to 2021 dominated by immunohistochemistry ... the largest share of immunohistochemistry (IHC) market, by end user.   ... , , ... across 225 pages, profiling 10 companies and supported with 181 tables ...
(Date:11/30/2016)... /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the Company") ... to announce the formation of EyGen, Ltd. a ... assets through proof of concept. EyGen,s lead asset ... Pharmaceuticals Limited and being developed for topical ophthalmic ... segment diseases. This agent has the potential to ...
(Date:11/30/2016)... and BEIJING , Nov. 30, ... commercial provider of genomic services and solutions with cutting ... that it has completed a USD $75 Million [515 ... Co., Ltd.,s CMB International Capital Management ( Shenzhen ... Management Co., Ltd. ("SDIC Innovation") and Shanghai Sigma Square ...
Breaking Biology Technology:
(Date:11/17/2016)... announces that it has just released a new white paper authored by Zettar that ... speed data transfer storage solutions. Photo - http://photos.prnewswire.com/prnh/20161116/440463 ... ... ... Setting up a high performance computing or HPC system can be a ...
(Date:11/15/2016)... Nov 15, 2016 Research and Markets has ... to 2021" report to their offering. ... ... Billion by 2021 from USD 6.21 Billion in 2016, growing at ... Growth of the bioinformatics market is driven by the growing demand ...
(Date:6/27/2016)... Research and Markets has announced the addition of the ... The report forecasts the biometrics ... a CAGR of 12.28% during the period 2016-2020. ... with inputs from industry experts. The report covers the market landscape ... includes a discussion of the key vendors operating in this market. ...
Breaking Biology News(10 mins):